PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Tytuł artykułu

Monte Carlo study on the gold and gadolinium nanoparticles radio-sensitizer effect in the prostate 125I seeds radiotherapy

Identyfikatory
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Monte Carlo and TL dosimetry applied to the characterization of 125I brachytherapy with a different design with other 125I seeds. In a water phantom, lattice configuration simulated with 125I seed in the center and 10 nm gold and gadolinium nan-particle filed voxels. This simulation conducted to the characterization of the nano-particles DEF in low energy and prostate tissue. To study of the prostate brachytherapy, a humanoid computational phantom developed by CT slices applied. KTMAN-2 computational phantom contains 29 organs and 19 skeletal regions and was produced from cross-sectional x-ray computed tomography (CT slices) images. The simulated seed was 125I seed having an average energy of 28.4 keV for photons, a half-life of 59.4 days. DEF factor in the seed radiation energy (28.4 keV) DEF factor was found to be two times higher for the gold nano-particles. It was revealed than gold-nano-particles posing Z about 1.24 times higher than gadolinium led to around 200% DEF increasing in the same conditions and the nano-particles size. It was concluded that in low energy sources brachytherapy, photoelectric is dominant in the presence of relative high element nanoparticles. This leads to a high dose increasing in some micro-meters and causes a dramatic dose gradient in the vicinity of a nano-particle. This dose gradient effectively kills the tumor cells in continuous low energy irradiation in the presence of a high Z material nano-scaled particle. Application of gold nano-particles in low energy brachytherapy is recommended.
Rocznik
Strony
165--169
Opis fizyczny
Bibliogr. 22 poz., rys., tab.
Twórcy
  • Medical Radiation Sciences Research Team, Tabriz University of Medical Sciences, Tabriz
  • Department of radiology and radiotherapy, Tabriz University of Medical Sciences, Tabriz
  • Medical Radiation Sciences Research Team, Tabriz University of Medical Sciences, Tabriz
Bibliografia
  • [1] Wisely CE, Hadziahmetovic M, Reem RE, et al. Long-term Visual Acuity Outcomes in Patients with Uveal Melanoma Treated with 125I Episcleral OSU-Nag Plaque Brachytherapy. Brachytherapy. 2016;15(1):12–22.
  • [2] Liu P, Tong T, Huo B, et al. CT-guided 125I brachytherapy for recurrent ovarian cancer. 2017;8(35):59766–59776.
  • [3] Chen F, Wang D. Inhibition of glioblastoma growth and invasion by 125I brachytherapy in rat glioma model. Am J Transl Res. 2017;9(5):2243-2254.
  • [4] Mazeron R, Bajard A, Montbarbon X, et al. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence. Radiat Oncol. 2012;7:45-46.
  • [5] Jiao D, Wu G, Ren J, Han X. Radiofrequency ablation versus 125I-seed brachytherapy for painful metastases involving the bone. Oncotarget. 2016;7(52): 87523-87531.
  • [6] Lin L, Guo L, Zhang W, et al. Novel Silicone-Coated 125I Seeds for the Treatment of Extrahepatic Cholangiocarcinoma. PLoS One. 2016;11(2):e0147701.
  • [7] Yao L, Cao Q, Wang J, et al. CT-Guided 125I Seed Interstitial Brachytherapy as a Salvage Treatment for Recurrent Spinal Metastases after External Beam Radiotherapy. Biomed Res Int. 2016;2016:8265907.
  • [8] Patel KR, Prabhu RS, Switchenko JM, et al. Visual acuity, oncologic, and toxicity outcomes with 103Pd vs. 125I plaque treatment for choroidal melanoma. Brachytherapy. 2017;16(3):646–653.
  • [9] Stish BJ, Davis BJ, Mynderse LA, et al. Low dose rate prostate brachytherapy. Transl Androl Urol. 2018;7(3):341-356.
  • [10] Xiang Z, Mo Z, Li G, et al. 125I brachytherapy in the palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments. Oncotarget. 2016;7(14):18384-18393.
  • [11] Lee YC, Lin SC, Kim Y. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using 125I COMS plaques. Radiat Oncol. 2018;13(1):221.
  • [12] Zhu Y, Dong M, Yang J, Zhang J. Evaluation of Iodine-125 Interstitial Brachytherapy Using Micro-Positron Emission Tomography/Computed Tomography with 18F-Fluorodeoxyglucose in Hepatocellular Carcinoma HepG2 Xenografts. Med Sci Monit. 2019;25:371-380.
  • [13] Teles P, Barros S, Cardoso S, et al. A dosimetric study of prostate brachytherapy using Monte Carlo simulations with a voxel phantom, measurements and a comparison with a treatment planning procedure. Radiat Protect Dosim. 2015;165(1-4):482-487.
  • [14] Davis BJ, Horwitz EM, Lee WR, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11:6-19.
  • [15] Wang C, Chen Z, Sun W, et al. Palliative treatment of pelvic bone tumors using radioiodine (125I) brachytherapy. World J Surg Oncol. 2016;14:294.
  • [16] Tan Q, Qin Q, Yang W, et al. Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study. Medicine (Baltimore). 2016;95(44):e5302.
  • [17] Han Q, Deng M, Lv Y, Dai G. Survival of patients with advanced pancreatic cancer after iodine-125 seeds implantation brachytherapy: A meta-analysis. Medicine (Baltimore). 2017;96(5):e5719.
  • [18] Rivard JM, Coursey BM, DeWerd LA, et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31(3):1-42.
  • [19] Luxton G. Comparison of radiation dosimetry in water and in solid phantom materials for 125I and 103Pd brachytherapy sources: EGS4 Monte Carlo study. Med. Phys. 1994;21(5):631-641.
  • [20] Chiu-Tsao ST, Anderson LL, O’Brien K, Sanna R. Dose rate determination for 125I seeds. Med Phys.1990;17(5):817-825.
  • [21] Chiu-Tsao ST, Anderson LL. Thermoluminescent dosimetry for Pd-103 (model 200) in solid water phantom. Med Phys.1991;18(3):449-452.
  • [22] Wang R, Sloboda RS. Monte Carlo dose parameters of brachyseed model LS-1 I-125 brachytherapy source. Applied Radiat Isotopes. 2001;56:805-813.
Uwagi
Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2020).
Typ dokumentu
Bibliografia
Identyfikator YADDA
bwmeta1.element.baztech-41f12e34-7dfd-432e-acaa-b4bcc6aab068
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.